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ABSTRACT 
Objective: Aim of this study was to develop and validate the RP-HPLC method using Box-Behnken Design (BBD) for simultaneous analysis 
metformin HCl and glimepiride in spiked plasma.  
Methods: The chromatographic system was comprised of acetonitrile-phosphate buffer 0.0125 M+Sodium Dodecyl Sulphate (SDS) 1 mmol as a 
mobile phase and Ascentis®
Results: The predicted optimum condition of the RP-HPLC system consisted of phosphate buffer solution of 72%, pH at 4.3 and flow rate at 0.8 
ml/min. By using this condition, the duration of analysis was more than 18 min, so it was necessary to modify the flow rate to be 1.0 ml/min to get 
shorter analysis duration. This condition was then applied to analyze metformin and glimepiride in spiked plasma and validated according to the 
EMA guideline. AUC of interfering components at the IS retention time between 588-1092 mV, the linearity of metformin was 0.9993 and 
glimepiride was 0.9991, accuracy and precision were between-13.33% until 16.08%, dilution integrity and metformin stability studies were 
between-4.01% until 11.82%, and for glimepiride stability studies were between-37.48% until-4.76%. 
 Phenyl C18 (250 x 4.6 mm i.d.; 5 µm) column as a stationary phase with UV detector at 210 nm. Three independent 
variables included phosphate buffer (%), pH and flow rate were optimized using Box-Behnken Design. The observed responses were retention time, 
peak area and resolution.  
Conclusion: Box-Behnken Design can help optimize the HPLC system, and the optimum condition was valid to analyze metformin and glimepiride 
in spiked plasma by considering the storage time of plasma samples.  
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INTRODUCTION 
Diabetes mellitus (DM) is one of the 10 causes of death in the 
world [1-2]. Monotherapy for patients with type 2 diabetes has 
often a failure to control glucose levels. Therefore, a combination 
therapy required to achieve target glycaemic goals [3]. A 
combination of metformin and sulfonylurea has been attached in 
many cases and indicates highly effective to control of glucose 
levels [4]. The uses of glimepiride as the second generation of 
sulphonylurea have some benefit in the effectivity in low dose, 
long duration, and the lower risk in older patients [5-6]. 
Monitoring and evaluation of the plasma level of these drugs are 
crucial for individual dose, pharmacokinetics as well as in 
bioequivalence studies [7–9]. 
Plasma is a biological sample that extremely complex matrices 
composed of many components that can disrupt the quantitative 
measurement of the drugs [10]. Therefore, high selectivity and 
sensitivity analytical method is needed. Various methods using 
HPLC and LC-MS/MS have been expands for the simultaneous 
quantification of metformin and glimepiride in plasma matrices [11–
19]. HPLC is one of the selected methods for analysis in this study, it 
is widely used for pharmaceutical analysis or bioanalysis and 
available in almost all analytical chemistry laboratories [20]. 
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Fig. 1: The chemical structure of metformin (A), glimepiride (B), and atenolol as internal standar (C) 
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Some parameters like the percentage of buffer solution in the mobile 
phase, pH and flow rate have a major effect on HPLC separation [21]. 
Box-Behnken Design is a multivariate analysis technique that can 
minimize the time and costs for the optimization process [22–24]. It 
was applied to various studies, like the isolation process, development 
of drug formulation, and optimization of chromatographic conditions 
[25–27]. Optimization of HPLC conditions using BBD has been applied 
for the analysis of various samples [28–30]. The predicted condition of 
HPLC obtained using BBD was applied for the simultaneous analysis of 
metformin and glimepiride in plasma and then was validated 
according to European Medicines Agency (EMA) guidelines. 
MATERIALS AND METHODS 
Reagents and materials 
Metformin working standard (99.5% purity; PT. Phapros, Tbk., 
Indonesia), glimepiride working standard (100.49% purity; PT. Phapros, 
Tbk., Indonesia), and atenolol reference standard (Sigma Aldrich, 
France), distilled water (PT. Brataco, Indonesia), acetonitrile HPLC grade 
(J. T. Baker, New Jersey), potassium dihydrogen phosphate p. a, sodium 
dodecyl sulphate (SDS) for ion pair chromatography (Sigma Aldrich, 
France), and blank human plasma collected from the Indonesian Red 
Cross in Yogyakarta-Indonesia was stored at-20 ᵒC until use.  
HPLC condition 
The LC system used for analysis was consisted of Hitachi UV-Vis L-
2420 detector (at 210 nm), Hitachi L-2130 HPLC pump, D-2000 HSM 
elite software, chromatographic column Ascentis®
Preparation of standard solutions 
 Phenyl C18 (250 
x 4.6 mm i.d.; 5 µm), and injection valve with a 20 µl loop. The 
mobile phase was composed of acetonitrile and phosphate buffer 
0.0125 M+SDS 1 mmol in various of pH, ratio and flow rate. Mobile 
phase was filtered through 0.45 µm pore filter and degassed using 
bath sonicator before use. 
The stock solution 1000 µg/ml of metformin and atenolol was 
processed separately by dissolving 10 mg in 10 ml methanol and 10 
mg in 10 ml methylene chloride for glimepiride in the volumetric 
flask. Each stock solution was diluted with methanol to achieve an 
intermediate solution of 20 and 100 µg/ml, and then the 
intermediate solution was diluted again with methanol to produce 
the working standard solutions (0.2-20 µg/ml). 
Experimental design 
The optimization of HPLC condition was conducted by the 
experimental design approach, Box-Behnken Design (BBD) using 
Design-Expert 11.0 software. In the preliminary study, the mobile 
phase used was a mixture of acetonitrile-phosphate buffer 0.0125 
M+SDS 1 mmol pH 4.00 (25:75) with a flow rate 1.0 ml/min. The 
independent variables in this study were the percentage of buffer 
composition in the mobile phase (X1) that optimized at 70-80%, pH 
of mobile phase (X2) was optimized at 3.5-4.5, and flow rate (X3
Preparation of spiked plasma sample 
) 
was optimized at 0.8-1.2 ml/min. The responses as dependent 
variables were retention time, peak area, and resolution. 
The preparation technique was modified from method of 
determining metfomin and glimepiride simultaneous in human 
serum [13]. Sample plasma was prepared by spiking working 
standard solutions of metformin, glimepiride and atenolol as 
internal standard. Aliquot of 750 µl blank plasma was spiking with 
500 µl comprising mixture working solution of metformin and 
glimepiride, and 100 µl of atenolol working solution. And then 3000 
µl acetonitrile as extraction solvent was added. The solution was 
shaken for 10 seconds, next centrifuged for 10 min at 15.000 rpm 4 
ᵒC. The supernatant was separated and made up 10.0 ml with mobile 
phase addition. This solution was filtered with PVDF 0.45 µm and 20 
µl injected into HPLC system. 
System suitability test 
System suitability test (SST) was executed by injecting the analytes 
(metformin and glimepiride, and internal standard) in plasma each 
at concentration of 1000 ng/ml in six replicates. Parameters were 
observed included resolution (Rs>2), asymmetry (As ≤ 2), height 
equivalent to the theoretical plate (HETP>2000), capacity factor 
(k>2), and % coefficient variance of peak area and retention time 
(%CV<2) [31]. 
Validation of HPLC analysis 
Validation of the HPLC method is based on the European Medicines 
Agency (EMA) guidelines by assessing several validation parameters 
namely selectivity, accuracy, and precision, curve calibration, LLOQ, 
carryover, and stability [32]. 
Selectivity 
Selectivity was recognized by comparing the chromatograms of the 
spiked samples and the blank plasma samples. For this purpose, the 
spiked sample of metformin, glimepiride, and atenolol as internal 
standard and blank plasma samples from six different sources were 
prepared and injected. Selectivity was analyzed to chromatographic 
interference around the retention times of metformin, glimepiride, 
and atenolol. Acceptance criteria for interfering component when 
the response is less than 20% of the lower limit of quantification for 
the analyte and 5% for the internal standard. 
Calibration curve 
Calibration curves were performed using blank plasma from a 
working standard solution. Calibration curves were assessed by 
preparing the calibration curve in the range of 15-1000 ng/ml for 
metformin and 10-1000 ng/ml for glimepiride. The internal 
standard of atenolol was added to each solution at a concentration of 
1000 ng/ml. Linear regression, slope, intercept, and % recovery was 
calculated from each concentration. The acceptance criteria were 
seen from the recovery results must be in the range of±20% for 
LLOQ and±15% for other concentrations and at least 75% of 
calibration standards, with a minimum of six calibration standard 
levels, must satisfy the requirements. 
Accuracy and precision 
The within-run (single run) and between-run (in different run) 
accuracy and precision were carried out using 4 concentration levels 
covered in the calibration curve range, namely LLOQ, low (3×LLOQ), 
medium (30-50% of the range of curves), and high (75% of the 
upper calibration curve range) which 5 replication for each 
concentration. The concentration of metformin were 15 ng/ml, 45 
ng/ml, 500 ng/ml and 750 ng/ml, and for glimepiride were 10 
ng/ml, 30 ng/ml, 500 ng/ml and 750 ng/ml and using atenolol as 
internal standard at 1000 ng/ml. The concentrations of metformin 
and glimepiride were determined using calibration curves acquired 
on the same days. Accuracy was approximated by comparing 
observed concentration with the nominal concentration as a mean 
percentage relative recovery, whereas precision was observed in 
%CV. The acceptance criteria for accuracy was % error of the mean 
of observed concentration that it should be ≤ 15% at the nominal 
concentration, except for LLOQ which was ≤ 20%. And the 
acceptance criteria for precision was the %CV no more than 15% of 
the sample concentration and for LLOQ no more than 20% of the 
sample concentration. 
LLOQ 
The lowest concentration that can be quantified with acceptable 
accuracy and precision (CV<20 %). 
Carry-over 
Carry-over was determined by injecting blank samples after a high 
concentration standard of metformin and glimepiride. The peak area 
at the retention time of metformin and glimepiride, and atenolol in 
the blank sample will not be greater than 20% of the lower limit of 
quantification (LLOQ) and 5% for the internal standard. 
Stability 
Stability of metformin and glimepiride in the plasma were checked at 
low (45 ng/ml for metformin and 30 ng/ml for glimepiride) and high 
(750 ng/ml) quality control (QC) samples. Stability assessment 
comprised of stability of analyte in plasma after reconstitution then 
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stored at room temperature (25±2 °C) for 24 h (autosampler stability), 
stability of analyte in plasma for 6 h at-80 °C, stability of analyte in 
plasma for 24 h at-80 °C, and stability of analyte after 3 cycles of freeze 
(-80±2 °C) and thaw (±25 °C) (freeze and thaw stability). 
RESULTS AND DISCUSSION 
Experimental design optimazitation 
Based on chemical structure, metformin and glimepiride have a 
distinctive polarity, therefore it was quite difficult to do separation 
by using HPLC. The use of experimental design by BBD was an 
alternative strategy to predict the optimum condition to separate 
these compounds. The effects of independent variables (composition 
of mobile phase, pH and flow rate) on the response variables (RT, Rs, 
peak area) from 17 experimental runs were analysed using 
statistical analysis ANOVA to obtain the polynomial equation to 
demonstrate the significant effect of independent variables on the 
response (dependent) variables. The complete results of responses 
values of BBD using independent variables are shown on table 1. 
A good model is determined by the significance value of effect from 
each factor on the response variables (p<0.05). A good model should 
provide a value R2>0.7, which means the equation model can be 
used to predict the optimum condition. The adjusted coefficient of 
determination (Adj. R2)>0.8 represent that the polynomial equation 
provides a good model where the difference of Adj. R2 from the 
predicted R2 (pred. R2
 
) should be less than 0.2. The positive value 
from the equation denotes a positive correlation between 
independent and dependent variables, while the negative value 
evidence a counter-correlation in both variables [33-35].
Table 1: Design of experiment-based box-behnken design using independent variables of % buffer (X1), pH (X2), and flow rate (X3
Run 
) with 
response variables of retention time, peak area, and resolution used in HPLC method development for analysis of metformin and glimepiride 





























1 75 4.5 1.2 6.49 9.80 12.72 99394.00 26081.00 28350.50 10.36 7.05 
2 75 3.5 0.8 10.88 15.07 19.52 153676.00 38786.00 43720.50 8.87 7.10 
3 80 4.0 1.2 14.93 0 27.73 124030.00 0 27194.50 0 14.14 
4 70 4.0 1.2 3.85 4.78 10.82 93464.50 24216.50 23003.50 4.21 20.01 
5 75 3.5 1.2 7.02 9.69 12.72 101183.00 27269.00 21684.00 8.56 7.54 
6 80 4.0 0.8 23.41 22.36 43.97 30325.00 149135.00 39602.00 1.35 13.72 
7 70 4.0 0.8 5.79 7.20 16.54 140165.00 36806.00 48234.00 4.23 12.19 
8 70 4.5 1.0 4.61 5.75 13.01 113718.00 30292.00 38432.50 4.50 20.25 
9 75 4.0 1.0 7.99 11.82 15.44 103414.00 30586.00 30823.00 10.73 7.75 
10 75 4.0 1.0 8.00 11.83 15.42 103509.00 30710.00 28427.00 10.64 7.61 
11 75 4.0 1.0 8.00 11.82 15.40 107210.00 28289.00 28759.50 10.56 7.57 
12 75 4.0 1.0 8.02 11.86 15.41 110011.00 25758.50 27371.50 10.62 7.43 
13 80 4.5 1.0 16.79 17.69 34.29 121873.00 27862.00 31916.00 1.47 17.89 
14 80 3.5 1.0 23.25 17.78 33.84 100480.00 41279.00 30577.00 7.20 9.72 
15 75 4.5 0.8 9.84 14.88 19.37 141520.00 38335.50 43729.00 10.53 7.58 
16 75 4.0 1.0 8.04 11.89 15.41 109732.00 26984.00 24249.00 10.53 7.30 
17 70 3.5 1.0 4.69 5.75 13.20 120870.00 31691.00 20523.30 4.30 20.27 
 
The ANOVA analysis obtained from the independent variables (X1, 
X2 and X3) and the retention time of metformin (Y1) produced a 
polynomial equation as follows:  
1/Y1 = 0.1248-0.0813 X1+0.0052 X2+0.0268 X3+0.0032 X1X2-
0.0157 X1X3+0.0005 X2X3+0.0107 X1 2-0.0023 X22-0.0000 X32 (Eq. 1) 
The statistical analysis from Equation 1 shows Adj. R2 = 0.9998 and 
Pred. R2 
The response variable Y
= 0.9967, which means that it is within the acceptable 
criteria. Press value was 0.0002, where the smaller value indicates a 
better model precision [34]. 
1 demonstrated the model was 
significant (p<0.05), this finding explained that the model could 
illustrate a significant effect of X 1 , X2 and X 3 on the response 
variable Y1 . of the three factors (X 1 , X 2 and X 3), X 1 exhibited the 
strongest effect on Y1 , although X 2 and X 3 
The interaction between the factors to the response can be seen 
from the 3D surface graph [36]. The 3D surface graph of metformin 
retention time was presented in fig. 2.




Fig. 2: The 3D surface graph of interaction between %buffer (X1) and pH (X2) (A); between pH (X2) and flow rate (X3) (B) on retention 
time of metformin (Y1) 
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The ANOVA analysis of atenolol retention time (Y2) produced a 
polynomial equation as follows:  
Y2 = 11.18+4.29 X1+0.0052 X2-4.41X3-0.0233 X1X2-
4.98X1X3+0.0750 X2X3
Equation 2 generates R
 (Eq. 2) 
2= 0.8259, Adj. R2= 0.7215, Pred. R2 = 0.1242 
and the difference value of Adj. R2and Pred. R2as 0.5973. The ANOVA 
analysis shows p<0.05 which means there was a significant effect 
between the factors and the observed response, although it did not 
satisfy the criteria as a good model as demonstrated by Adj. R2<0.8 
and the difference between Adj. R2and Pred. R2>0.2. The response Y2 
was significantly affected by factor X1 and X3
A quadratic polynomial equation for glimepiride retention time (Y




was described as follows:  
3 = 2.74+0.4787 X1-0.0011X2-0.2167 X3+0.0069 X1X2-0.0092 
X1X3+0.0020 X2X3+0.3165 X12-0.0015 X22+0.0214 X32
Equation 3 yields p<0.05 which means there was a significant 
correlation between the factor and the observed response with 
R
(Eq. 3) 
2= 0.9999, Adj. R2= 0.9998, Pred. R2= 0.9990, the difference 
between Adj. R2and Pred. R2was<0.2 and PRESS 0.0028. Retention 





Fig. 3: The 3D surface graph of interaction between %buffer (X1) and pH (X2) (A); between pH (X2) and flow rate (X3) (B) on retention 




Fig. 4: The 3D surface graph of interaction between %buffer (X1) and flow rate (X3) (A); between pH (X2) and flow rate (X3) (B) on 




Fig. 5: The 3D surface graph of interaction between %buffer (X1) and flow rate (X3) (A); between pH (X2) and flow rate (X3) (B) on the 
peak area of metformin (Y4) 
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Similarly, the equation for Y4, Y5, Y6, Y7 and Y8 were:  
Y4 = 1.103E+05-11438.65 X1+36.98 X2-5951.75 X3+7136.42 
X1X2+35101.38 X1X3+2591.87 X2X3 (R2= 0.5755, Adj. R2= 0.3208 
and Pred. R2
The above model shows an insignificant effect (p>0.05), its means 
the factors of X
=-1.1445) (Eq. 4) 
1, X2, and X3 were not correlated with Y4 [32]. The 3D 
surface graph of Y4 was presented in fig. 5. 
 = 177.54+7.09 X1-5.63 X2-61.06 X3-8.07 X1X2-87.49 X1X3-
0.6225 X2X3 (R2= 0.7847, Adj. R20.6555, Pred. R2
The ANOVA analysis of Y
= 0.0773) (Eq. 5) 
5 had p<0.05, which means there was a 
significant effect between the factors and the observed response, 
although it did not satisfy the criteria as a good model as 
demonstrated by Adj. R2<0.8 and the difference between Adj. R2and 




Fig. 6: The 3D surface graph of interaction between %buffer (X1) and flow rate (X3) (A); between pH (X2) and flow rate (X3) (B) on the 
peak area of atenolol (Y5
 
) 
Y6 = 27926.00-112.98 X1+3240.40 X2-9381.63 X3-4142.54 
X1X2+3205.75 X1X3+1664.50 X2X3+1286.85 X1 2+1149.35 
X2 2+5295.65 X32 (R2= 0.9537, Adj. R2= 0.8941 and Pred. R2
The response of Y
= 0.5631) 
(Eq. 6) 
6 demonstrates a significant effect (p<0.05). The 
factor of X1, X2 and X3 were observed to have an effect on Y5,  but 
only X2 and X3 
 
were found to act significantly (fig. 7).
 
Fig. 7: The 3D surface graph of interaction between %buffer (X1) and pH (X2) (A); between %buffer (X1) and flow rate (X3) (B) on the 
peak area of glimepiride (Y6
 
) 
Y7 = 10.62-0.9040 X1-0.2571 X2-0.2319 X3-1.48 X1X2-0.3325 
X1X3+0.0337 X2X3-6.69 X12+0.4401 X2 2-1.48 X32(R2= 0.9309, Adj. 
R2= 0.8421 and Pred. R2
Y8 = 7.53-2.16 X
=-0.1041)(Eq. 7) 
1+1.02 X2+1.02 X3+2.05 X1X2-1.85 X1X3-0.2437 
X2X3+8.60 X12+0.9028 X22-1.12 X32 (R2= 0.9389, Adj. R2= 0.8604 and 
Pred. R2
The Y
= 0.0270)(Eq. 8) 
7 and Y8 models demonstrated a significant correlation 
(p<0.05) between the factors and the observed response variables, 
which highly affected by X 1. The 3D surface graph of Y7 was 
presented in fig. 8, and for Y8 
Based on the eight equations above, the Design Expert 11.0 software 
can predict the optimum condition with selected criteria. These 
criteria were presented in table 2. And the optimum condition 
obtained from the Design Expert 11.0 software can be seen in fig. 10. 
was presented in fig. 9. 
The predicted optimum condition was comprised of phosphate 
buffer at 72%, pH at 4.3 with flow rate of 0.8 ml/min. Fig. 11 showed 
chromatograph of metformin, atenolol and glimepiride produced 
using the optimum condition on plasma sample. It can be seen that 
the duration time of analysis was too long. Therefore, the flow rate 
was increased to 1.0 ml/min to shorten duration of the analysis. As 
shown on fig. 12, by using flow rate at 1.0 ml/min, the retention time 
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of glimepiride became 14 min, shorter than it from initial method 
using 0.8 ml/min. And under these conditions, there was also did not 
find interfering peaks from the matrix. This condition was then 
chosen for system suitability test and validation method. 
 
 









Table 2: The criteria of factors and responses for determining the optimum condition 
Name Goal Lower limit Upper limit Importance* 
A: %Bufer is in range 70 80 3 
B: pH is in range 3.5 4.5 3 
C: FR is in range 0.8 1.2 3 
RT Metf Minimize 7 9 5 
RT Ate is in range 9.5 11 3 
RT Glim is in range 10 15.5 5 
PA Metf is in range 30325 153676 3 
PA Ate is in range 0 149135 3 
PA Glim Maximize 20523.3 48234 5 
Rs 1 Minimize 2 20 3 
Rs 2 Minimize 2 20 3 
*5: most important, 4: important, 3: middle important, 2: less important, 1: not important 
 
Based on these results, it can be seen that the optimum conditions 
predicted by a statistical approach cannot always be applied 
directly, especially in multiple compounds analysis. Besides, a 
sample with the complex matrix was also considered in the 
optimization process because generally there will be produced a 
peak from the matrix that can interfere the signal.
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Fig. 10: The optimum condition of HPLC predicted by design expert 11.0 software 
 
 
Fig. 11: HPLC chromatogram of metformin, glimepiride and atenolol 1000 µg/ml, respectively in plasma matrix run at predicted optimum 
condition (buffer at 72%, buffer pH 4.3 with flow rate 0.8 ml/min) 
 
 
Fig. 12: HPLC chromatogram of metformin, glimepiride and atenolol 1000 µg/ml, respectively in plasma matrix run at buffer at 72%, 
buffer pH 4.3 with flow rate 1.0 ml/min 
 
System suitability test 
Some parameters of system suitability test (SST), namely resolution, 
asymmetry, height equivalent to the theoretical plate (HETP), k, peak 
area, and retention time were evaluated. And based on the results of the 
SST of metformin and glimepiride, and atenolol as internal standard in 
spiked plasma showed that the condition of the optimized HPLC method 
satisfy the SST requirements i.e. resolution>2, asymmetry ≤ 2, 
HETP>2000, k>2, and %CV of peak area and retention time<2. These 
results indicate that the HPLC system was running well and effectively 
for the quantitative analysis of metformin and glimepiride. The results of 
system suitability test are presented in table 3.
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Table 3: System suitability test results of the optimum condition of the HPLC method 
Parameters Result Acceptance criteria 
Retention time of metformin 0.00** ≤ 2 
Retention time of glimepiride 0.28** ≤ 2 
Retention time of atenolol 0.07** ≤ 2 
Peak area of metformin 0.44** ≤ 2 
Peak area of glimepiride 1.72** ≤ 2 
Peak area of atenolol 1.84** ≤ 2 
Asymmetry of metformin 1.25±0.02* ≤ 2 
Asymmetry of glimepiride 1.35±0.04* ≤ 2 
Asymmetry of atenolol 1.18±0.02* ≤ 2 
Resolution 1 (between metformin and atenolol) 6.11±0.04* >2 
Resolution 2 (between atenolol and glimepiride) 14.78±0.10* >2 
Number of theorical plates of metformin 7987.33±77.55* >2000 
Number of theorical plates of glimepiride 11648.33±81.99* >2000 
Number of theorical plates of atenolol 7227.50±104.50* >2000 
k of metformin 2.76±0.00* >2 
k of glimepiride 8.27±0.03* >2 
k of atenolol 3.99±0.01* >2 




The result of selectivity parameter showed that six individuals 
independent samples analyzed were satisfied with the selectivity 
requirements according to the EMA guidelines. Peak area of 
endogenous compounds at the retention time of analyte were less 
than 20% of the LLOQ of analyte and<5% for IS (table 4). These 
indicate that the method was selective for analysis of metformin and 
glimepiride in the plasma sample.
 
Table 4: Selectivity data of metformin and glimepiride 
Replication 5% of the AUC of IS: 1150 mV Result 
Blank plasma 1 588 <20% and<5% 
Blank plasma 2 665 <20% and<5% 
Blank plasma 3 0 <20% and<5% 
Blank plasma 4 1092 <20% and<5% 
Blank plasma 5 0 <20% and<5% 
Blank plasma 6 1065 <20% and<5% 
*There was no signal in the retention time of metformin and glimepiride 
 
Linearity 
The linearity of the calibration curve of metformin and glimepiride 
was assessed from the coefficient of correlation (r-value) and the 
recovery of the nominal value. The linearity was explaining the 
correlation between analyte concentration (x-axis) and the ratio of 
AUC of analyte to AUC of internal standard (y-axis). The analyte 
concentrations used in this research were 15-1000 ng/ml for 
metformin and 10-1000 ng/ml for glimepiride (fig. 13). The method 
exhibited a good correlation with r-value more than of 0.99 
(UNODC, 2009) i.e. 0.9993 for metformin and 0.9991 for 
glimepiride, respectively. The recovery results met the EMA 
requirements i.e. <20% for LLOQ and<15% for other concentrations 
of the nominal value.
 
 
Fig. 13: The calibration curves of metformin and glimepiride between concentration of analyte (x-axis) and ratio of the peak area of 
analyte to the peak area of IS (y-axis) 
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Accuracy and precision 
Accuracy and precision studies were conducted using 4 levels 
analyte concentration in spiked plasma namely at LLOQ, low, 
medium and high-quality control (QC) samples which 5 replications 
for metformin and glimepiride, respectively. The results of accuracy 
study both within-run and between-run accuracy were satisfied 
with the EMA guidelines requirements i.e. %error of the mean of 
observed concentration was ≤ 15% of the nominal concentration, 
except for LLOQ which was ≤ 20%. The results of the precision study 
also met the validation requirements based on EMA guidelines, 
namely % CV values were<15% for the QC samples and<20% for 
LLOQ. The values obtained for within-run and between-run accuracy 
and precision of metformin and glimepiride were summarized in 
tables 5 and 6. And the data for extraction recoveries were shown in 
table 7.
  
Table 5: Within-run and between-run accuracy and precision data for metformin assays in spiked plasma (n=5) 
Nominal concentration (ng/ml) % error %CV 
Within (n=5) Between (n=5) Within (n=5) Between (n=5) 
Day 1 Day 2 Day 3 Day 1 Day 2 Day 3 
14.92 16.08 2.72 -1.65 5.72 1.81 9.00 2.45 8.72 
44.77 3.72 9.85 12.20 8.59 4.20 5.47 1.15 4.39 
497.50 -3.09 1.55 10.69 3.05 2.87 0.33 3.21 6.55 
746.25 3.53 8.13 3.89 5.18 2.73 1.95 3.68 2.74 
 
Table 6: Within-run and between-run accuracy and precision data for glimepiride assays in spiked plasma (n=5) 
Nominal concentration (ng/ml) %error %CV 
Within (n=5) Between (n=5) Within (n=5) Between (n=5) 
Day 1 Day 2 Day 3 Day 1 Day 2 Day 3 
10.03 7.43 11.47 -9.10 3.45 2.19 0.83 0.04 9.64 
30.12 -1.50 -13.33 1.94 -4.37 2.43 2.33 6.50 8.67 
501.95 0.57 -5.76 9.43 1.53 2.42 5.74 1.34 7.57 
752.92 -9.94 1.61 -0.27 -2.74 1.22 1.95 2.30 6.14 
 
Table 7: Recovery data for metformin and glimepiride assays in spiked plasma (n=15) 
Nominal concentration (ng/ml) mean±SD of measurable concentration (ng/ml) %CV 
Metformin 
14.92 15.78±1.37 8.69 
44.77 48.62±2.13 4.39 
497.50 512.68±33.61 6.55 
746.25 784.92±21.49 2.74 
Glimepiride 
10.03 10.47±1.81 17.34 
30.12 28.85±2.50 8.67 
501.95 504.85±35.15 6.96 
752.92 728.44±44.00 6.04 
 
LLOQ 
The obtained LLOQ were 15 ng/ml for metformin and 10 ng/ml for 
glimepiride. These concentrations have to satisfy the EMA guidelines 
requirements, namely the value of the % error of recovery i. e<20% 
and % recovery in the range of 80-120%. 
Dilution integrity 
The results of the dilution integrity study have to satisfy the 
acceptance criteria i.e. accuracy and precision within±15%. These 
results indicated the method can be used to analyze a sample over 
ULOQ concentration after the convenient dilution.
 
Table 8: The result of dilution integrity study of metformin and glimepiride 
Dilution factor Metformin Glimepiride 








2x 992.03 -0.35 3.61 997.37 -4.01 4.05 
5x 396.81 7.54 3.79 398.95 11.82 3.46 
 
Carryover 
Carryover was analyzed by injecting a blank plasma after the higher 
concentration standard solution. There was no carryover detected in 
three blank samples, analyzed after the higher concentration 
standard solution. EMA guidelines requirement for carryover is the 
peak area at the retention time of analyte doesn't exceed 20% for 
LLOQ and 5% for IS. Carryover study results can be seen in table 8.
 
Table 9: Carryover data of metformin and glimepiride 
Replication 5% of the IS area: 1150 mV Result 
Blank plasma 1 606 <20% and<5% 
Blank plasma 2 855 <20% and<5% 
Blank plasma 3 0 <20% and<5% 
*There was no signal in the retention time of metformin and glimepiride 
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Stability 
A stability study was carried out to determine the stability of the 
analyte during the preparation and storage process. There was no 
significant degradation of metformin after the samples were stored 
under various conditions. Stability of glimepiride after stored at-80 
ᵒC for 6 h was assured. However, there was a significant decrease of 
glimepiride concentration after 24 h storage at-80 ᵒC, the samples 
evaluation in the freeze and thaw stability, and the extracted 
samples keeping in the auto-sampler at 25 ᵒC for 24 h (table 9). 
Glimepiride instability was estimated due to the chemical structure 
of glimepiride contain sulfonylurea bridges, carboxamides, β-lactam 
rings, and α-β unsaturated carbonyl systems that caused the drug 
impressionable to degradation by photolysis or hydrolysis [37]. 
The results of the stock solution stability showed that the stock 
solution from metformin was still stable for 56 d. This was indicated 
by %error less than 15%. i. e-3.61% for T0 and 9.21% for T56. The 
results of stock solution stability of glimepiride showed an increased 
glimepiride concentration after 30 d of storage, the %error of T0 
was 1.43% and for T30
 
 was 35.65%. Methylene chloride which used 
to dissolve glimepiride was a very volatile solvent, so the stock 
solutions become more concentrated and the measured 
concentration becomes larger.
Table 10: Stability data for metformin and glimepiride assay in spiked plasma 
Stability study mean±SD of measurable concentration (ng/ml) Accuracy (%error) Precision (%CV) 
Metformin 
T Low QC 6 49.53±3.04 10.62 6.14 
High QC 782.23±17.83 4.82 2.28 
T Low QC 24 42.14±3.15 -5.88 7.48 
High QC 822.44±17.32 10.21 2.11 
Freeze and Thaw Low QC 43.09±4.68 -3.77 10.87 
High QC 781.79±45.95 4.76 5.88 
auto-sampler 995.00 ng/ml 951.57±5.17 -4.36 0.54 
Glimepiride 
T Low QC 6 28.77±1.05 -4.76 3.64 
High QC 709.07±53.50 -6.11 7.55 
T Low QC 24 20.40±2.33 -32.46 11.41 
High QC 593.79±13.24 -21.38 2.23 
Freeze and Thaw Low QC 18.89±1.28 -37.48 6.78 
High QC 623.11±32.83 -17.50 5.27 
auto-sampler 1006.99 ng/ml 845.13±265.99 -16.07 31.47 
 
The research using LC-MS/MS was very sensitive methods and 
produced a very low of LOQ, but the high of operational cost caused 
a problem in the laboratory. The method in this study has several 
advantages compared to the previously developed HPLC method, 
namely this study can reduce the number of SDS usage, so it can 
reduce the negative effect of SDS on the column. Based on the cost, 
this method was more cost-effective because the preparation 
technique carried out by protein precipitation compared to using 
the SPE technique. LOQ value in this study smaller compared to 
other research who also carried out the sample preparation using 
the protein precipitation technique [13, 18]. The comparison of the 
new method and the previous methods that have been developed 
were summarized in table 11. 
The method developed in this study was still in vitro, it will be better 
in further research conducted in vivo study, so the metabolic 
compounds of metformin and glimepiride can be evaluated. 
Furthermore, it is necessary to conduct a study that causes 
glimepiride instability, so it can be corrected when applying to the 
bioavailability and bioequivalence study.
 
Table 11: Summary of the simultaneous determination of metformin and glimepiride in plasma 
Parameters HPLC LC-MS/MS 








Previous method-4 [17] 
















Metformin: 10-10000 ng/ml 
Glimepiride: 4-4000 ng/ml 
LOQ Metformin: 15 ng/ml 
Glimepiride: 10 
ng/ml 
Metformin: 5 ng/ml 









Metformin: 10 ng/ml 
Glimepiride: 4 ng/ml 
Mobile phase ACN: buffer KH2PO4 2 mmol SDS in ACN: 
buffer KH
 
0.0125 M+SDS 1 




pH 3.0 (90:10%, 
v/v) 
 0.0125 




Gradient elution of methanol 
(containing 5 mmol/l 
ammonium acetate) and 5 
mmol/l aqueous ammonium 
acetate 
 0.025 M pH 





x 4,6 mm i.d.; 5 µm) 
C18 Supelco analytical 
column (250 × 4,6 mm 
i.d., 5 µm) 
Purospher® MAGELLEN 5U C18 
(150 × 4.60 mm., 5 
μm) 
 Star 
C18 (25 × 0,46 cm 
i.d., 5 µm) 













protein precipitation using 
methanol 
Flow rate 1.0 ml/min 1.0 ml/min 1.0 ml/min 1.0 ml/min 0.8 ml/min 
Wavelength 210 nm 225 nm 231 nm 234 nm - 
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CONCLUSION 
The design expert of Box-Behnken could be used for optimization 
HPLC conditions to analyze metformin, glimepiride and atenolol as 
an internal standard for spiked plasma samples. The predicted 
condition produced from BBD, sometimes has to adjusted in order to 
get the optimum time of analysis. The optimum condition of HPLC 
resulted from this research was comprised of the mixture 28%:72% 
of acetonitrile-phosphate buffer 0.0125 M+SDS 1 mmol as mobile 
phase, pH adjusted at 4.3 and flow rate at 1.0 ml/min. This optimum 
condition was valid to quantify metformin and glimepiride in spiked 
plasma by considering the storage time of plasma samples. 
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